PubMed Health⌕ Search

Biomedical subjects

R Kotitschke

Publications and source records attributed to R Kotitschke.

22 records · Page 2Linked to original sources
PubMed1982

Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).

The association of viral hepatitis, type B, with the use of prothrombin complex concentrates (PPSB) has been well documented. PPSB prepared from cold-sterilized plasma (beta-propiolactone treated and UV irradiated) has been shown not to induce hepatitis in chimpanzees. 500 U of cold-sterilized PPSB were infused into 5 healthy male volunteers. Previous to, and up to 6 months after, PPSB-application in addition to careful clinical investigations, the following hepatitis parameters were determined: SGOT, SGPT, y-GT, alkaline phosphatase, total serum bilirubin, HBsAg, HBcAb and HBsAb. On the basis of all of the above parameters there was no indication of induction of viral hepatitis following the application of PPSB prepared from beta-propiolactone/UV treated plasma.

Adult↗
PubMed1981

Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees.

Recent experiments have shown that a preparation of PPSB (factor IX concentrate) derived form beta PL/UV treated plasma was not infectious in chimpanzees with respect to hepatitis B and non-A, non-B. To answer the question whether the beta PL/UV treatment influences the tolerance and efficacy of the PPSB-concentrate, long-term application of PPSB-Biotest was carried out in chimpanzees. After 10 applications of 25 U factor IX/kg at weekly intervals, no signs of intolerance were observed by measurement of blood pressure during i.v. application and by means of skin-testing. Determination of coagulation factor activity during the application period revealed the same factor IX recovery at the beginning and at the end of the study.

Animals↗
PubMed1980

[Serologic hepatitis B markers in porphyria cutanea tarda (author's transl)].

Using several seromarkers for hepatitis B virus the frequency of previous hepatitis B in patients with porphyria cutanea tarda (PCT) as a possible manifestation factor was determined. As chronic hepatitis is frequently associated with an increase of factor VIII-associated antigen, this was included in the investigation. Results make it likely that 28 out of 60 investigated patients (47%) have had hepatitis. In 30% an increase of factor VIII-associated antigen was found. It can be assumed that hepatitis B virus infection as a manifestation factor may be of considerable importance in porphyria cutanea tarda when genetic disposition (uroporphyrinogen-decarboxylase deficiency) is present.

Antigens↗